Kamada targets higher CYTOGAM use as post-marketing studies expand in lung transplant CMV prophylaxis
KMDA•Kamada expands post-marketing research for CYTOGAM
- Kamada plans to expand post-marketing research to build evidence supporting increased CYTOGAM utilization in solid organ transplantation.
- The program targets CMV management in high-risk transplant patients, with a focus on outcomes beyond viral suppression, including immune modulation.
- Management expects additional study readouts later in 2026, with full results from the latest investigator-initiated work slated for publication this year.
